Delving into the Latest Updates on Dexmecamylamine Hydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Dexmecamylamine, Dexmecamylamine hydrochloride (USAN), S(+)-mecamylamine

+ [4]

Target

nAChR α4/β2/α5 x nAChRα3&β4

Mechanism

Nicotinic acetylcholine receptor alpha4/beta2/alpha5 antagonists, α3β4 receptor antagonists(Neuronal acetylcholine receptor; alpha3/beta4 antagonists)

Therapeutic Areas

Other DiseasesSkin and Musculoskeletal DiseasesUrogenital Diseases+ [1]

Active Indication-

Inactive Indication

Depressive Disorder, MajorDrug abuseHyperhidrosis+ [3]

Originator Organization

Catalyst Biosciences, Inc.

Active Organization-

Inactive Organization

AstraZeneca PLCTargacept, Inc.

Atacama Therapeutics, Inc.Startup

Drug Highest PhaseDiscontinuedPhase 3

First Approval Date-

Regulation-

Login to view timeline

Structure

Molecular FormulaC11H22ClN

InChIKeyPKVZBNCYEICAQP-GSTSRXQZSA-N

CAS Registry107596-30-5

View All Structures (2)

This is a multicenter, randomized, double-blind, placebo-controlled, parallel group comparison study of AT-5214 in subjects with moderate to severe primary palmar hyperhidrosis (sweaty palms). This study will compare two different oral (tablet) doses of AT-5214 (study drug) versus a matched placebo. Approximately 120 subjects will be enrolled at approximately 10 study sites.

Start Date31 Jan 2020

Sponsor / Collaborator

Atacama Therapeutics, Inc.Startup

NCT03404570 / CompletedPhase 2

A Double-Blind, Randomized, Placebo-Controlled Exploratory Study to Assess the Efficacy and Safety of TC-5214 in the Treatment of Subjects With Moderate to Severe Palmar Hyperhidrosis

This is a pilot exploratory study to evaluate the safety and efficacy of TC-5214 in subjects with palmar hyperhidrosis.

Start Date21 Dec 2017

Sponsor / Collaborator

Atacama Therapeutics, Inc.Startup

100 Clinical Results associated with Dexmecamylamine Hydrochloride

Login to view more data

100 Translational Medicine associated with Dexmecamylamine Hydrochloride

Login to view more data

100 Patents (Medical) associated with Dexmecamylamine Hydrochloride

Login to view more data

15

Literatures (Medical) associated with Dexmecamylamine Hydrochloride

01 Dec 2024·Neuroscience

S-(+)-mecamylamine increases the firing rate of serotonin neurons and diminishes depressive-like behaviors in an animal model of stress

Article

Author: Rojano-Posada, Y. ; Hernández-González, O. ; Garduño, J. ; Francia-Ramírez, D ; Rojano-Posada, Y ; Ortega-Tinoco, S ; Francia-Ramírez, D. ; Mondragón-García, A. ; Ramírez-Sánchez, E. ; Mondragón-García, A ; Verdugo-Díaz, L ; Ortega-Tinoco, S. ; Ramírez-Sánchez, E ; Hernández-López, S ; Garduño, J ; Hernández-López, S. ; Verdugo-Díaz, L. ; Hernández-González, O

Mecamylamine, a noncompetitive blocker of nicotinic acetylcholine receptors (nAChRs), is the racemic mixture of two stereoisomers: S-(+)-mecamylamine (S-mec) and R-(-)-mecamylamine (R-mec), with distinct interactions with α4β2 nAChRs. It has been shown that mecamylamine increases glutamate release and excites serotonergic (5-HT) neurons in the dorsal raphe nucleus (DRN). In this study, we separately evaluated the effects of S-mec and R-mec on 5-HT neuron excitability. S-mec (3 μM) increased firing frequency by 40 %, while R-mec (3 μM) raised it by only 22 %. S-mec acts as a positive allosteric modulator on high-sensitivity (HS) α4β2 nAChRs at glutamate terminals, enhancing spontaneous excitatory postsynaptic currents (sEPSCs) in 5-HT neurons. Conversely, R-mec decreased sEPSCs by blocking HS α4β2 nAChRs and reduced GABA-mediated inhibitory currents (sIPSCs) by blocking α7 nAChRs at GABAergic terminals. These mechanisms make S-mec more effective than R-mec in enhancing 5-HT neuron firing. Moreover, combining S-mec with TC-2559, a selective agonist of HS α4β2 nAChRs, increased firing frequency by 65 %, exceeding the effect of S-mec alone. To validate these findings, we evaluated the antidepressant effects of S-mec (1 mg/kg) combined with TC-2559 or RJR-2403, another α4β2 nAChR agonist. This combination successfully reduced depression-like behaviors, suggesting a potential treatment strategy for patients resistant to conventional antidepressants.

01 Jul 2022·PsychopharmacologyQ3 · MEDICINE

Ropanicant (SUVN-911), an α4β2 nicotinic acetylcholine receptor antagonist intended for the treatment of depressive disorders: pharmacological, behavioral, and neurochemical characterization

Q3 · MEDICINE

Article

Author: Abraham, Renny ; Thentu, Jagadeesh Babu ; Palacharla, Veera Raghava Chowdary ; Jayarajan, Pradeep ; Pandey, Santosh Kumar ; Mohammed, Abdul Rasheed ; Goura, Venkatesh ; Subramanian, Ramkumar ; Kallepalli, Rajesh ; Jasti, Venkat ; Petlu, Surendra ; Gagginapally, Shankar Reddy ; Medapati, Rajesh Babu ; Goyal, Vinod Kumar ; Tadiparthi, Jayaprakash ; Nirogi, Ramakrishna

RATIONALERopanicant (SUVN-911) (3-(6-Chloropyridine-3-yloxymethyl)-2-azabicyclo (3.1.0) hexane hydrochloride) is a novel α4β2 nicotinic acetylcholine receptor (nAChR) antagonist being developed for the treatment of depressive disorders.OBJECTIVESPharmacological and neurochemical characterization of Ropanicant to support a potential molecule for the treatment of depressive disorders.METHODSRopanicant was assessed for antidepressant-like activity using the rat forced swimming test (FST) and differential reinforcement of low rate -72 s (DRL-72 s). Alleviation of anhedonia was assessed in chronic mild stress model using sucrose preference test. To understand the mechanism of action, serotonin levels, ionized calcium-binding adaptor molecule 1 (Iba1), and brain-derived neurotrophic factor (BDNF) were determined. The onset of antidepressant-like activity was determined using the reduction in submissive behavior assay. The effects on cognition and sexual functions were assessed using the object recognition task and sexual dysfunction assay respectively. Interaction of Ropanicant, TC-5214, and methyllycaconitine (MLA) with citalopram was investigated individually in mice FST.RESULTSRopanicant exhibited antidepressant like properties in the FST and DRL-72 s. A significant reduction in anhedonia was observed in the sucrose preference test. Oral administration of Ropanicant produced a significant increase in serotonin and BDNF levels, with a reduction in the Iba1 activity. The onset of antidepressant like effect with Ropanicant was within a week of treatment, and was devoid of cognitive dulling and sexual dysfunction. While Ropanicant potentiated the effect of citalopram in FST, such an effect was not observed with MLA or TC-5214.CONCLUSIONSPreclinical studies with Ropanicant support the likelihood of its therapeutic utility in the treatment of depressive disorders.

01 Nov 2015·Journal of UrologyQ1 · MEDICINE

Clinical Efficacy and Tolerability of the Nicotinic Channel Modulator Dexmecamylamine in Subjects with Overactive Bladder

Q1 · MEDICINE

Article

Author: Chancellor, Michael ; Toler, Steven ; Versi, Eboo ; Dvergsten, Chris

PURPOSEWe evaluated the efficacy and tolerability of the nicotinic channel modulator dexmecamylamine for overactive bladder.MATERIALS AND METHODSThis was a randomized, double-blind, placebo controlled trial in 768 randomized subjects. Those with at least a 6-month history of overactive bladder were randomized to 0.5, 1 or 2 mg dexmecamylamine or placebo in a ratio of 1:1:1:2, respectively. Subjects completed a 3-day diary before each visit associated with the 12-week treatment period. They were required to have 8 or more micturitions per day and 3 or more urinary urge incontinent episodes per day if overactive bladder wet at the end of a placebo run-in period. Co-primary end points for the study included a change from baseline 1) in micturition frequency per 24 hours at week 12 and 2) in urge urinary incontinence episodes per 24 hours at week 12. Secondary end points were voided volume, nocturia episodes, OABq (Overactive Bladder Questionnaire) and urgency questionnaire.RESULTSDexmecamylamine (2 mg) produced a statistically significant decrease in micturition frequency (p = 0.03) but did not produce a statistically significant decrease in urge incontinence (wet) episodes (p = 0.38). Secondary end points, including volume voided in the 1 mg group only, CGI-I (Clinical Global Impression of Improvement), visual analog scale urgency impact, intensity and severity, were statistically significant at week 12 for the 2 mg dose. Dexmecamylamine was well tolerated in this subject population with a low incidence of discontinuations due to adverse effects. Constipation, dry mouth and urinary tract infection showed a dose dependent increase in frequency.CONCLUSIONSDexmecamylamine does not appear to offer an enhanced therapeutic profile for the treatment of overactive bladder relative to current therapies.

100 Deals associated with Dexmecamylamine Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D10112	-	-	DB11807

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Depressive Disorder, Major	Phase 3	IN	Targacept, Inc.	01 Jun 2010
Depressive Disorder, Major	Phase 3	PR	AstraZeneca PLC	01 Jun 2010
Depressive Disorder, Major	Phase 3	IN	Targacept, Inc.	01 Jun 2010
Depressive Disorder, Major	Phase 3	PR	AstraZeneca PLC	01 Jun 2010
Depressive Disorder, Major	Phase 3	US	Targacept, Inc.	01 Jun 2010
Major depressive disorder, moderate (MDD)	Phase 3	US	Targacept, Inc.	01 Jun 2010
Major depressive disorder, moderate (MDD)	Phase 3	IN	AstraZeneca PLC	01 Jun 2010
Major depressive disorder, moderate (MDD)	Phase 3	US	AstraZeneca PLC	01 Jun 2010
Major depressive disorder, moderate (MDD)	Phase 3	IN	Targacept, Inc.	01 Jun 2010

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01153347 (CTgov)	Phase 3	Depressive Disorder, Major	2,409	TC-5214 (0.5 mg BID TC-5214)	cehdeoqpui(vpnplqbwny) = gfsqrvcesl tbiaknintv (uwjunbgiib, fmdamnyjkh - zuvlxotzxy) View more	-	20 Nov 2012
				TC-5214 (2 mg BID TC-5214)	cehdeoqpui(vpnplqbwny) = wvlojnofxa tbiaknintv (uwjunbgiib, mqnsqxrvcu - kkkprbxrll) View more
NCT01180400 (CTgov)	Phase 3	Depressive Disorder, Major	295	TC-5214 (TC-5214)	bloamdgdve(uuxschfcwh) = upppkysdhb rzwtpedfah (zigkvsrknc, uhldyktwlx - mxhjcjlnvp) View more	-	20 Nov 2012
				Placebo (Placebo)	bloamdgdve(uuxschfcwh) = fxqmnblivg rzwtpedfah (zigkvsrknc, fbrfcoibxe - pxsadslbls) View more
NCT01157078 (CTgov)	Phase 3	Major depressive disorder, moderate (MDD) \| Depressive Disorder, Major	319	TC-5214 (TC-5214)	zcnqeubbvj(yxwuthnkns) = uwtvbmcrwg qwexwttzxs (styytfohsm, imoqsfngqi - xmcnkvhomb) View more	-	20 Nov 2012
				Placebo (Placebo)	zcnqeubbvj(yxwuthnkns) = dsjlgllnzv qwexwttzxs (styytfohsm, zkserqmuzn - jbqmhydqvb) View more
NCT01197508 (CTgov)	Phase 3	Depressive Disorder, Major	696	TC-5214 (0.1 mg BID TC-5214)	ukebiurhbo(arpivodreh) = blkcddjlig zxfbkcihgo (xfoemtcpru, jwvdripkhj - ovjeaorzde) View more	-	29 Oct 2012
				TC-5214 (1 mg BID TC-5214)	ukebiurhbo(arpivodreh) = remknysjxs zxfbkcihgo (xfoemtcpru, ukaaaiuokj - ehvsdpdhpo) View more
NCT01152554 (CTgov)	Phase 3	Depressive Disorder, Major	813	Serotonin+TC-5214 (TC-5214)	zrevbthnmx(zsahzzjuui) = uvzatvbion qutaqwcfef (urtzetbrvf, uxcmuzxtxb - mebvxksmrm) View more	-	29 Oct 2012
				Selective serotonin reuptake (Placebo)	zrevbthnmx(zsahzzjuui) = oebojpveun qutaqwcfef (urtzetbrvf, ffkolnsvqs - rlkkfpimld) View more